Fitbit invests $6M in Sano, a company that makes a coin-sized patch to track blood sugar; this is Fitbit's first startup investment
Context & Ripple Effects
The $100M IPO filing that valued Fitbit at about $4.1B in mid-2015 rested on strong hardware margins and $132M of net income; the years since have eroded that foundation amid low-margin consumer devices. The $6M Sano investment — small by M&A standards, and notably an equity stake rather than the outright purchase Fitbit made when it paid at least $17.8M for Fitstar — marks a shift from buying finished products to seeding sensor technology.
Sano's coin-sized blood sugar patch points past step counting toward continuous metabolic monitoring, a direction Fitbit later followed with the blood oxygen monitoring rollout across its wearables. As Fitbit's first startup investment, it also signals the company treating its balance sheet as a way to build a health pipeline rather than only ship hardware.
First-order effects
- Sano gains capital plus a strategic partner whose device fleet could eventually distribute or validate its patch, while Fitbit secures an early option on noninvasive glucose tracking without paying an acquisition premium upfront.
- Fitbit investors get a signal that management is redirecting cash from pure hardware cycles toward differentiated health features that could command pricing power over commodity trackers.
Second-order effects
- Rival wearable makers face pressure to match biometric depth beyond activity metrics, since a credible blood sugar capability would reset what consumers expect a wrist-worn device to measure.
- Sensor startups in adjacent biomarkers gain a template for strategic exits: minority checks from device makers who want the technology de-risked before committing to full acquisitions.
Third-order effects
- If the pattern holds, wearables consolidate into health platforms where the durable value sits in validated physiological data rather than device sales — a trajectory consistent with Fitbit's later absorption into Google's account system and health stack.
- Consumer biosensing drifts toward regulated territory, forcing device makers to build clinical-evidence capabilities they historically lacked, and giving regulators a larger role in what a fitness band may claim to measure.
The trend: Consumer wearables are evolving from fitness accessories into health-monitoring platforms, with device makers investing in or acquiring biosensor startups instead of building the science in-house.